Tag: fibrinolysis

Posted on

Decreasing delayed cerebral infarction after aneurysmal subarachnoid hemorrhage using active blood clearance and prevention of delayed cerebral ischemia: results of a 16-year patient registry

J Neurosurg 143:928–938, 2025

Active blood clearance and prevention of delayed cerebral ischemia (ABCD) after aneurysmal subarachnoid hemorrhage significantly reduced delayed cerebral infarction rates and improved outcomes in high-risk patients, using methods like intrathecal irrigation, urokinase, and nimodipine, according to a 16-year registry study.

Active blood clearance and prevention of delayed cerebral ischemia (ABCD) was introduced for patients with aneurysmal subarachnoid hemorrhage (aSAH) to reduce delayed cerebral infarction (DCI) using methods like intrathecal irrigation, fibrinolysis with urokinase, and intrathecal nimodipine.

• Four ABCD methods were developed: stereotactic catheter ventriculocisternostomy (STX-VCS), intraoperative cisternoventricular catheter (CVC), ventriculolumbar irrigation (VLI), and lumbo-lumbar irrigation (LLI).

• Implementation of ABCD in high-risk patients led to a significant reduction in DCI rates from 21.2% to 7.7% and a 70% decrease in per-patient DCI burden.

• Patients selected for ABCD had higher initial blood load and worse clinical status, but still showed improved outcomes, especially those with high Hijdra scores (≥30).

• Pressure-controlled VLI and intraoperative CVC emerged as the most practical and widely applicable ABCD techniques.

• Complication rates were low and ABCD was considered safe, with rare adverse events and no increase in infection rates.

• The study suggests ABCD outperforms previous DCI prevention strategies and recommends multicenter trials for further validation.

Posted on

Nonsurgical treatment of chronic subdural hematoma with tranexamic acid

SDH

J Neurosurg 119:332–337, 2013

Chronic subdural hematoma (CSDH) is a common condition after head trauma. It can often be successfully treated surgically by inserting a bur hole and draining the liquefied hematoma. However, to the best of the authors’ knowledge, for nonemergency cases not requiring surgery, no reports have indicated the best approach for preventing hematoma enlargement or resolving it completely. The authors hypothesized that hyperfibrinolysis plays a major role in liquefaction of the hematoma. Therefore, they evaluated the ability of an antifibrinolytic drug, tranexamic acid, to completely resolve CSDH compared with bur hole surgery alone.

METHODS
From 2007 to 2011, a total of 21 patients with CSDH seen consecutively at Kuki General Hospital, Japan, were given 750 mg of tranexamic acid orally every day. Patients were identified by a retrospective records review, which collected data on the volume of the hematoma (based on radiographic measurements) and any complications. Follow-up for each patient consisted of CT or MRI every 21 days from diagnosis to resolution of the CSDH.

RESULTS
Of the 21 patients, 3 with early stages of CSDH were treated by bur hole surgery before receiving medical therapy. The median duration of clinical and radiographic follow-up was 58 days (range 28–137 days). Before tranexamic acid therapy was initiated, the median hematoma volume for the 21 patients was 58.5 ml (range 7.5–223.2 ml); for the 18 patients who had not undergone surgery, the median hematoma volume was 55.6 ml (range 7.5–140.5 ml). After therapy, the median volume for all 21 patients was 3.7 ml (range 0–22.1 ml). No hematomas recurred or progressed.

CONCLUSIONS
Chronic subdural hematoma can be treated with tranexamic acid without concomitant surgery. Tranexamic acid might simultaneously inhibit the fibrinolytic and inflammatory (kinin-kallikrein) systems, which might consequently resolve CSDH. This medical therapy could prevent the early stages of CSDH that can occur after head trauma and the recurrence of CSDH after surgery.

Proudly powered by WordPress